The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), Johnson & Johnson (Gold) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2018 | Does TP53-mutated clonal size impact outcomes of CLL patients from the MURANO study?
The MURANO study (NCT02005471) is a Phase III trial looking at rituximab in combination with either bendamustine or venetoclax for the treatment of refractory chronic lymphocytic Leukemia (CLL). A key aim of the study is to assess whether mutated TP53 clone size affects treatment efficacy. Here, Arnon Kater, PhD, of Universiteit Van Amsterdam, Amsterdam, Netherlands, describes the interesting early results from a side study of the MURANO trial. Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Prof. Kater mentions that further results are needed to draw conclusions, and should be released at the end of the year.
